BioSpace News Archive

Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market.

Allerpops, a local allergy-relief business, today announced the approval of a clinical trial for its product promoting all-natural allergy relief.

Eurofins Viracor, LLC, a leader in testing for infectious disease, immunology, and allergy, announced today that it has entered into an exclusive license agreement with Cornell University to commercialize several ground-breaking and novel assays aimed at transforming the clinical management of COVID-19 and transplant patients impacted from tissue damage and infections.

It offers various social programs and activities through the use of the volunteers and is supported in this endeavor by the Center for Empowerment and Elder Care (Ehsan).

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2022.

MaaT Pharma (EURONEXT: MAAT – the “Company”), announced today that positive results from its Phase 2 trial HERACLES (NCT03359980, n=24) and from its compassionate use program (EAP, n=52) for lead microbiome therapy MaaT013 will be reported in an oral presentation at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation.

Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), today announced that, pursuant to Belgian transparency legislation1, it had received two transparency notifications following the closing of its private placement, which was announced on March 7, 2022.

A vertebral compression fracture is a type of spinal disorder that may cause due to arthritis, osteoporosis, and trauma.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the appointment of Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., as independent members of Adverum’s Board of Directors.

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021.